<page><title>SATB2-associated syndrome</title><url>https://medlineplus.gov/genetics/condition/satb2-associated-syndrome</url><content>SATB2-associated syndrome
To use the sharing features on this page, please enable JavaScript.
Description
SATB2
-associated syndrome is a condition that affects several body systems. It is characterized by intellectual disability, severe speech problems, dental abnormalities, abnormalities of the head and face (craniofacial anomalies), and behavioral problems. Some of the common features can be described using the acronym SATB2 (which is the name of the gene involved in the condition): severe speech anomalies, abnormalities of the palate, teeth anomalies, behavioral issues with or without bone or brain anomalies, and onset before age 2.
Individuals with
SATB2
-associated syndrome typically have mild to severe intellectual disability, and their ability to speak is delayed or absent. Development of motor skills, such as rolling over, sitting, and walking, can also be delayed. Many affected individuals have behavioral problems, including hyperactivity and aggression. Some exhibit autistic behaviors, such as repetitive movements. A happy or overly friendly personality is also common among individuals with
SATB2
-associated syndrome. Less common neurological problems include feeding difficulties and weak muscle tone (hypotonia) in infancy. About half of affected individuals have abnormalities in the structure of the brain.
The most common craniofacial anomalies in people with
SATB2
-associated syndrome are a high arch or an opening in the roof of the mouth (
high-arched
or
cleft palate
), a small lower jaw (micrognathia), and dental abnormalities, which can include abnormally sized or shaped teeth, extra (supernumerary) teeth, or missing teeth (oligodontia). Some people with
SATB2
-associated syndrome have other unusual facial features, such as a prominent forehead, low-set ears, or a large area between the nose and mouth (a
long philtrum
). People with this disorder may also have a shortage of minerals, such as calcium, in bones (decreased bone mineral density), which makes the bones brittle and prone to fracture.
Less-commonly affected are the heart, genitals and urinary tract (genitourinary tract), skin, and hair.
Frequency
SATB2
-associated syndrome is a rare condition. Its prevalence is unknown.
Causes
SATB2
-associated syndrome is caused by genetic changes that affect the
SATB2
gene
. These include changes within the
SATB2
gene itself and deletions of large pieces of DNA from
chromosome 2
that remove the
SATB2
gene and other nearby genes. The
SATB2
gene provides instructions for making a protein that is involved in the development of the brain and structures in the head and face. The SATB2 protein directs development by controlling the activity of multiple genes in a coordinated fashion.
Researchers suspect that genetic changes affecting the
SATB2
gene reduce the amount of functional SATB2 protein. Reduction of SATB2 function likely impairs normal development of the brain and craniofacial structures, leading to intellectual disability, delayed speech, craniofacial anomalies, and other features of
SATB2
-associated syndrome.
The signs and symptoms of
SATB2
-associated syndrome are usually similar, regardless of the type of alteration that causes it. However, uncommon features of the condition, such as problems with the heart, genitourinary tract, skin, or hair, tend to occur in individuals with large deletions. Researchers suspect these features are related to the loss of other genes near
SATB2
.
Learn more about the gene and chromosome associated with SATB2-associated syndrome
SATB2
chromosome 2
Inheritance
SATB2
-associated syndrome is not typically inherited. It results from new (de novo) changes in the gene that occur during the formation of reproductive cells (eggs or sperm) or in early embryonic development. Affected individuals have no history of the disorder in their family.
Other Names for This Condition
2q32 deletion syndrome
2q33.1 microdeletion syndrome
Chromosome 2q32-q33 deletion syndrome
Glass syndrome
SAS
Additional Information &amp; Resources
Genetic Testing Information
Genetic Testing Registry: Chromosome 2q32-q33 deletion syndrome
Patient Support and Advocacy Resources
National Organization for Rare Disorders (NORD)
Catalog of Genes and Diseases from OMIM
GLASS SYNDROME; GLASS
Scientific Articles on PubMed
PubMed
References
Bengani H, Handley M, Alvi M, Ibitoye R, Lees M, Lynch SA, Lam W, Fannemel M,
Nordgren A, Malmgren H, Kvarnung M, Mehta S, McKee S, Whiteford M, Stewart F,
Connell F, Clayton-Smith J, Mansour S, Mohammed S, Fryer A, Morton J; UK10K
Consortium; Grozeva D, Asam T, Moore D, Sifrim A, McRae J, Hurles ME, Firth HV,
Raymond FL, Kini U, Nellaker C, Ddd Study, FitzPatrick DR. Clinical and molecular
consequences of disease-associated de novo mutations in SATB2. Genet Med. 2017
Aug;19(8):900-908. doi: 10.1038/gim.2016.211. Epub 2017 Feb 2.
Citation on PubMed
Britanova O, Akopov S, Lukyanov S, Gruss P, Tarabykin V. Novel transcription
factor Satb2 interacts with matrix attachment region DNA elements in a
tissue-specific manner and demonstrates cell-type-dependent expression in the
developing mouse CNS. Eur J Neurosci. 2005 Feb;21(3):658-68. doi:
10.1111/j.1460-9568.2005.03897.x.
Citation on PubMed
Britanova O, de Juan Romero C, Cheung A, Kwan KY, Schwark M, Gyorgy A, Vogel
T, Akopov S, Mitkovski M, Agoston D, Sestan N, Molnar Z, Tarabykin V. Satb2 is a
postmitotic determinant for upper-layer neuron specification in the neocortex.
Neuron. 2008 Feb 7;57(3):378-92. doi: 10.1016/j.neuron.2007.12.028.
Citation on PubMed
Britanova O, Depew MJ, Schwark M, Thomas BL, Miletich I, Sharpe P, Tarabykin
V. Satb2 haploinsufficiency phenocopies 2q32-q33 deletions, whereas loss suggests
a fundamental role in the coordination of jaw development. Am J Hum Genet. 2006
Oct;79(4):668-78. doi: 10.1086/508214. Epub 2006 Aug 30.
Citation on PubMed
or
Free article on PubMed Central
Dobreva G, Chahrour M, Dautzenberg M, Chirivella L, Kanzler B, Farinas I,
Karsenty G, Grosschedl R. SATB2 is a multifunctional determinant of craniofacial
patterning and osteoblast differentiation. Cell. 2006 Jun 2;125(5):971-86. doi:
10.1016/j.cell.2006.05.012.
Citation on PubMed
Mouille M, Rio M, Breton S, Piketty ML, Afenjar A, Amiel J, Capri Y,
Goldenberg A, Francannet C, Michot C, Mignot C, Perrin L, Quelin C, Van Gils J,
Barcia G, Pingault V, Maruani G, Koumakis E, Cormier-Daire V. SATB2-associated
syndrome: characterization of skeletal features and of bone fragility in a
prospective cohort of 19 patients. Orphanet J Rare Dis. 2022 Mar 3;17(1):100.
doi: 10.1186/s13023-022-02229-5.
Citation on PubMed
Zarate YA, Fish JL. SATB2-associated syndrome: Mechanisms, phenotype, and
practical recommendations. Am J Med Genet A. 2017 Feb;173(2):327-337. doi:
10.1002/ajmg.a.38022. Epub 2016 Oct 24.
Citation on PubMed
Zarate YA, Kalsner L, Basinger A, Jones JR, Li C, Szybowska M, Xu ZL, Vergano
S, Caffrey AR, Gonzalez CV, Dubbs H, Zackai E, Millan F, Telegrafi A, Baskin B,
Person R, Fish JL, Everman DB. Genotype and phenotype in 12 additional
individuals with SATB2-associated syndrome. Clin Genet. 2017 Oct;92(4):423-429.
doi: 10.1111/cge.12982. Epub 2017 Mar 7.
Citation on PubMed
Zarate YA, Steinraths M, Matthews A, Smith WE, Sun A, Wilson LC, Brain C,
Allgove J, Jacobs B, Fish JL, Powell CM, Wasserman WW, van Karnebeek CD, Wakeling
EL, Ma NS. Bone health and SATB2-associated syndrome. Clin Genet. 2018
Mar;93(3):588-594. doi: 10.1111/cge.13121. Epub 2017 Dec 27.
Citation on PubMed
The information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.
Official websites use .gov
A
.gov
website belongs to an official government
              organization in the United States.
Secure .gov websites use HTTPS
A
lock
(
Lock
Locked padlock icon
) or
https://
means youâ€™ve safely connected to
              the .gov website. Share sensitive information only on official,
              secure websites.</content></page>